(Q35579309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

title

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

author name string

M Flendrie

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

M C W Creemers

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

P M J Welsing

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

P L C M van Riel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

language of work or name

English

0 references

publication date

1 November 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

Annals of the Rheumatic Diseases

19 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

62 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

ii30-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

19 December 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766750

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766750

What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766750

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766750

Experience with etanercept in an academic medical center: are infection rates increased?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766750

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766750

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766750

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766750

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766750

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

12 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14532145

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14532145

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14532145

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/ARD.62.SUPPL_2.II30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14532145%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

PubMed publication ID

14532145

1 reference